NO905301L - Malaria - vaksine. - Google Patents

Malaria - vaksine.

Info

Publication number
NO905301L
NO905301L NO90905301A NO905301A NO905301L NO 905301 L NO905301 L NO 905301L NO 90905301 A NO90905301 A NO 90905301A NO 905301 A NO905301 A NO 905301A NO 905301 L NO905301 L NO 905301L
Authority
NO
Norway
Prior art keywords
malaria
infection
repeating
parasites
immunogenic determinants
Prior art date
Application number
NO90905301A
Other languages
English (en)
Norwegian (no)
Other versions
NO905301D0 (no
Inventor
Mitchell Stuart Gross
Daniel Matthew Gordon
Michael Richard Hollingdale
Original Assignee
Smithkline Beecham Corp
Us Army
Biomedical Res Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp, Us Army, Biomedical Res Inst filed Critical Smithkline Beecham Corp
Publication of NO905301D0 publication Critical patent/NO905301D0/no
Publication of NO905301L publication Critical patent/NO905301L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO90905301A 1989-12-08 1990-12-07 Malaria - vaksine. NO905301L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US44774689A 1989-12-08 1989-12-08

Publications (2)

Publication Number Publication Date
NO905301D0 NO905301D0 (no) 1990-12-07
NO905301L true NO905301L (no) 1991-06-10

Family

ID=23777585

Family Applications (1)

Application Number Title Priority Date Filing Date
NO90905301A NO905301L (no) 1989-12-08 1990-12-07 Malaria - vaksine.

Country Status (18)

Country Link
EP (1) EP0432965A1 (fr)
JP (1) JPH0673097A (fr)
KR (1) KR910011897A (fr)
CN (1) CN1053814A (fr)
AU (1) AU634837B2 (fr)
CA (1) CA2031468A1 (fr)
FI (1) FI906051L (fr)
HU (1) HUT56882A (fr)
IE (1) IE904412A1 (fr)
IL (1) IL96579A0 (fr)
MA (1) MA22097A1 (fr)
MY (1) MY105313A (fr)
NO (1) NO905301L (fr)
NZ (1) NZ236357A (fr)
PL (1) PL288140A1 (fr)
PT (1) PT96132A (fr)
ZA (1) ZA909838B (fr)
ZW (1) ZW19090A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ233255A (en) * 1989-04-11 1993-02-25 Chiron Corp Plasmodium cs protein analogues lacking one or more of the repeat epitopes, and containing at least one nonrepeat flanking epitope
US5972351A (en) * 1992-04-03 1999-10-26 Isis Innovation Limited Plasmodium falciparum MHC class I-restricted CTL epitopes derived from pre-erythrocytic stage antigens
ES2127829T3 (es) * 1992-07-31 1999-05-01 Medeva Holdings Bv Expresion de proteinas recombinantes fusionadas en bacterias atenuadas.
CA2168459C (fr) * 1993-07-30 2002-10-01 Mohammed Anjam Khan Proteines de fusion contenant le c-terminal de la toxine du tetanos liee a une proteine heterologue
GB9401787D0 (en) 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccine compositions
CA2171562A1 (fr) * 1993-09-10 1995-03-16 Carla Cerami Compositions et methodes pour empecher l'invasion des hepatocytes par les sporozoites de la malaria
GB9401795D0 (en) * 1994-01-31 1994-03-23 Medeva Holdings Bv Vaccines
GB2295394B (en) * 1994-01-31 1997-09-24 Medeva Holdings Bv DNA encoding a fusion protein comprising the C fragment of tetanus toxin
AU2003294482A1 (en) * 2002-11-20 2004-06-15 Stephen L Hoffman Method for the prevention of malaria

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN86100979A (zh) * 1985-02-07 1986-12-17 史密丝克莱恩贝克曼公司 疟疾疫苗的制备方法
IT1196501B (it) * 1986-07-16 1988-11-16 Eniricerche Spa Polipeptide utile per la preparazione di vaccini per la malaria e di kits diagnostici per la determinazione di affezioni malariche
FI884485A7 (fi) * 1987-01-30 1988-09-29 Smithkline Biologicals S A P. falciparumin sporotsoiitin pintaproteiinin muodostuminen hiivassa
CA2015722A1 (fr) * 1989-05-03 1990-11-03 Mitchell S. Gross Vaccin contre le paludisme

Also Published As

Publication number Publication date
PT96132A (pt) 1991-09-30
NZ236357A (en) 1993-01-27
ZW19090A1 (en) 1991-04-10
HU908128D0 (en) 1991-06-28
IL96579A0 (en) 1991-09-16
IE904412A1 (en) 1991-06-19
HUT56882A (en) 1991-10-28
KR910011897A (ko) 1991-08-07
MY105313A (en) 1994-09-30
FI906051A7 (fi) 1991-06-09
CN1053814A (zh) 1991-08-14
PL288140A1 (en) 1991-10-21
ZA909838B (en) 1992-05-27
MA22097A1 (fr) 1991-12-31
JPH0673097A (ja) 1994-03-15
EP0432965A1 (fr) 1991-06-19
NO905301D0 (no) 1990-12-07
FI906051L (fi) 1991-06-09
AU634837B2 (en) 1993-03-04
FI906051A0 (fi) 1990-12-07
CA2031468A1 (fr) 1991-06-09
AU6777490A (en) 1991-06-13

Similar Documents

Publication Publication Date Title
ES2150493T3 (es) Adyuvantes para vacunas contra el virus sincitico respiratorio.
NO922275D0 (no) Aryletere, deres fremstilling og fremgangsmaate for behandling
NO893769L (no) Fremgangsmaate for behandling av naturgass.
IT1229845B (it) Procedimento per la preparazione di perfluoropolieteri perossidici.
FI953608A7 (fi) Rokoteyhdisteet ja menetelmä immuunireaktion aikaansaamiseksi limakalv ossa järjestelmällisellä rokottamisella
MX9204625A (es) Composicion farmaceutica para el tratamiento de una especie de mamifero, que sufre de deficiencia cardiaca congestiva.
NO912825D0 (no) Fremgangsmaate for fremstilling av cokonjugate vaksiner omfattende immunogenisk protein, hiv-beslektede peptider og anioniske grupper.
NO905301L (no) Malaria - vaksine.
IL102092A0 (en) Vaccine and treatment method for human immunodeficiency virus
DK0765333T3 (da) Quillajasaponinadjuvans og vaccineformulering, der indeholder denne
ITBO910182A1 (it) Apparecchiatura per trattamenti di emodiafiltrazione.
PL376964A1 (pl) Leczenie miażdżycy tętnic przez bierne uodpornienie peptydem
DE68918712D1 (de) Rekombinante Eimeria tenella-Vakzine.
DK0975360T3 (da) Bovint respiratorisk og enterisk coronavirus som vaccine
DK0388223T3 (da) Ny fremgangsmåde til induktion af ovulation hos mennesker
DK56389D0 (da) Forhindring og behandling af retroviralt frembragte sygdomme
NO934055D0 (no) Fremgangsmaate for utvinning av dimetylamin- eller trimetylamindehydrogenaser, dehydrogenaser utvunnet ved denne og anvendelse av dem
DK0802796T3 (da) Kyllingeanæmimiddel-slagtekyllingevaccine
NO893948L (no) Bornitrogenpolymerer, fremgangsmaate for deres fremstilling og anvendelse som forloepere.
ITAL910005A1 (it) Processo per la realizzazione di strutture protesiche dentali.
ES2113549T3 (es) Metodo para inhibir la replicacion de vih empleando il-4.
DK0910405T3 (da) Vaccine, som indeholder caprint arthritis-encephalitis-virus, og anvendelse til immunbeskyttelse imod HIV-1-infektion
RU97107260A (ru) Способ профилактики послеоперационных гнойно-септических осложнений
EP0320034A3 (fr) Peptides synthétiques immunologiquement actifs utilisables pour préparer un vaccin contre le paludisme
FI930519A7 (fi) Peptiidejä HIV-viruksen aiheuttaman infektion torjumiseksi sekä menete lmä niiden käyttämiseksi